Latest Breaking News On - Richarde uihlein - Page 1 : comparemela.com

UPDATE – Galectin Therapeutics Reports Financial Results

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin.

United statesRicharde uihleinBenjamins carsonJoel lewisJack callicuttPol boudesGalectin therapeutics incInternational study evaluating the efficacyCompany contactExchange commissionDrug administrationCompany annual report on formCompany quarterly report on formAmerican association of liver diseases meetingQuarterly reportChief executive officer

Galectin Therapeutics Announces Nomination of Dr Benjamin S Carson, Sr to Board of Directors

12.10.2023 - NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the . Seite 1

Richarde uihleinJohns hopkins hospitalGalectin therapeutics chartAlectin therapeutics kursAlectin therapeutics aktie

Galectin Therapeutics (GALT) Appoints Benjamin S Carson, Sr to its Board

Galectin Therapeutics (GALT) Appoints Benjamin S Carson, Sr to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Richarde uihleinBenjamins carsonGalectin therapeutics incGalectin therapeuticsJohns hopkins hospital

As Stakes Rise, State Supreme Courts Become Crucial Election Battlegrounds

Pivotal issues like abortion, gerrymandering and voting have been tossed into state justices’ laps. Politicians, ideological PACs and big money are following.

United statesNorth carolinaPat dewineRicharde uihleinHerbertm kritzerMichaelj klarmanPat fischerJustice michellem kellerJoseph fischerWilliamk weisenbergKennethc griffinDouglas keithTony eversJennifer brunnerDemocratic partyOhio state bar association

Galectin Therapeutics : Announces $60 Million Credit Line from Richard E Uihlein Sufficient to Cover Expected Expenditures Through 2024 - Form 8-K

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 .

Joel lewisRicharde uihleinJack callicuttCompany annual report on formInternational study evaluating the efficacyCompany contactDrug administrationGalectin therapeutics incGalectin therapeutics announcesCover expectedGalectin therapeuticsNew drug applicationApplicable federal ratePromissory noteChief executive officerSeamless adaptive phase